Cargando…

TGF-β Polymorphisms Are a Risk Factor for Chagas Disease

Transforming growth factor β1 (TGF-β1) is an important mediator in Chagas disease. Furthermore, patients with higher TGF-β1 serum levels show a worse clinical outcome. Gene polymorphism may account for differences in cytokine production during infectious diseases. We tested whether TGFB1 polymorphis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferreira, Roberto Rodrigues, Madeira, Fabiana da Silva, Alves, Gabriel Farias, Chambela, Mayara da Costa, Curvo, Eduardo de Oliveira Vaz, Moreira, Aline dos Santos, Almeida de Sá, Renata, Mendonça-Lima, Leila, Cabello, Pedro Hernan, Bailly, Sabine, Feige, Jean-Jacques, Araujo-Jorge, Tania Cremonini, Saraiva, Roberto Magalhães, Waghabi, Mariana Caldas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835243/ https://www.ncbi.nlm.nih.gov/pubmed/29670670 http://dx.doi.org/10.1155/2018/4579198

Ejemplares similares

Correlation of transforming growth factor-β1 and tumour necrosis factor levels with left ventricular function in Chagas disease
por: Curvo, Eduardo OV, et al.
Publicado: (2018)

The Search for Biomarkers and Treatments in Chagas Disease: Insights From TGF-Beta Studies and Immunogenetics
por: Ferreira, Roberto Rodrigues, et al.
Publicado: (2022)

Transforming growth factor-ß as a therapeutic target for the cardiac damage of Chagas disease
por: Waghabi, Mariana Caldas, et al.
Publicado: (2022)

TGF-β inhibitor therapy decreases fibrosis and stimulates cardiac improvement in a pre-clinical study of chronic Chagas’ heart disease
por: Ferreira, Roberto Rodrigues, et al.
Publicado: (2019)

Cruzipain Activates Latent TGF-β from Host Cells during T. cruzi Invasion
por: Ferrão, Patrícia Mello, et al.
Publicado: (2015)

Selenium, TGF-Beta and Infectious Endemic Cardiopathy: Lessons from Benchwork to Clinical Application in Chagas Disease
por: Araujo-Jorge, Tania C., et al.
Publicado: (2022)

In Chagas disease, transforming growth factor beta neutralization reduces Trypanosoma cruzi infection and improves cardiac performance
por: Ferreira, Roberto Rodrigues, et al.
Publicado: (2022)

Impact of pharmaceutical care on the quality of life of patients with Chagas disease and heart failure: randomized clinical trial
por: da Silva, Gilberto M Sperandio, et al.
Publicado: (2012)

Oral Administration of GW788388, an Inhibitor of Transforming Growth Factor Beta Signaling, Prevents Heart Fibrosis in Chagas Disease
por: de Oliveira, Fabiane L., et al.
Publicado: (2012)

Indeterminate form of Chagas disease: historical, conceptual, clinical, and prognostic aspects
por: Hasslocher-Moreno, Alejandro Marcel, et al.
Publicado: (2021)

Letters to the Editor: Indeterminate form of Chagas Disease: some immunological insights
por: Hasslocher-Moreno, Alejandro Marcel, et al.
Publicado: (2022)

A Phosphoproteomic Approach towards the Understanding of the Role of TGF-β in Trypanosoma cruzi Biology
por: Ferrão, Patrícia M., et al.
Publicado: (2012)

Scrutinizing the Biomarkers for the Neglected Chagas Disease: How Remarkable!
por: Pinho, Rosa T., et al.
Publicado: (2016)

Chagas disease mortality during the coronavirus disease 2019 pandemic: A Brazilian referral center experience
por: Hasslocher-Moreno, Alejandro Marcel, et al.
Publicado: (2022)

Biomarkers and Echocardiographic Predictors of Cardiovascular Outcome in Patients With Chronic Chagas Disease
por: Mendes, Veronica G., et al.
Publicado: (2023)

Adverse drug events and the associated factors in patients with chronic Chagas disease
por: Lopes, Luiza Braz da Cunha, et al.
Publicado: (2020)

Discussing the Score of Cardioembolic Ischemic Stroke in Chagas Disease
por: Mendes, Fernanda de Souza Nogueira Sardinha, et al.
Publicado: (2020)

Impact of COVID-19 In-hospital Mortality in Chagas Disease Patients
por: Sperandio da Silva, Gilberto Marcelo, et al.
Publicado: (2022)

FIRST REPORT OF ACUTE CHAGAS DISEASE BY VECTOR TRANSMISSION IN RIO DE JANEIRO STATE, BRAZIL
por: SANGENIS, Luiz Henrique Conde, et al.
Publicado: (2015)

Corrigendum: Impact of COVID-19 in-hospital mortality in chagas disease patients
por: Sperandio da Silva, Gilberto Marcelo, et al.
Publicado: (2022)

Cardiac Chagas Disease: MMPs, TIMPs, Galectins, and TGF-β as Tissue Remodelling Players
por: da Costa, Arthur Wilson Florencio, et al.
Publicado: (2019)

Suppression of TGF‐β/Smad2 signaling by GW788388 enhances DENV‐2 clearance in macrophages
por: Teixeira, Gabrielly Sbano, et al.
Publicado: (2022)

Ageing with Chagas disease: an overview of an urban Brazilian cohort in Rio de Janeiro
por: Vizzoni, Alexandre Gomes, et al.
Publicado: (2018)

Prevalence of metabolic syndrome and associated factors among patients with chronic Chagas disease
por: Xavier, Isis Gabrielli Gomes, et al.
Publicado: (2021)

Chagas heart disease: An overview of diagnosis, manifestations, treatment, and care
por: Saraiva, Roberto M, et al.
Publicado: (2021)

Temporal changes in the clinical-epidemiological profile of patients with Chagas disease at a referral center in Brazil
por: Hasslocher-Moreno, Alejandro Marcel, et al.
Publicado: (2021)

Two-dimensional strain derived parameters provide independent predictors of progression to Chagas cardiomyopathy and mortality in patients with Chagas disease
por: Saraiva, Roberto M., et al.
Publicado: (2022)

Analysis of Three-Dimensional Scar Architecture and Conducting Channels by High-Resolution Contrast-Enhanced Cardiac Magnetic Resonance Imaging in Chagas Heart Disease
por: Santos, João Bosco de Figueiredo, et al.
Publicado: (2022)

Benznidazole/Itraconazole Combination Treatment Enhances Anti-Trypanosoma cruzi Activity in Experimental Chagas Disease
por: Assíria Fontes Martins, Tassiane, et al.
Publicado: (2015)

Translational research in Chagas disease: perspectives in nutritional therapy emerging from selenium supplementation studies as a complementary treatment
por: de Araujo-Jorge, Tania C, et al.
Publicado: (2022)

Macrophage P2X7 Receptor Function Is Reduced during Schistosomiasis: Putative Role of TGF-β1
por: Oliveira, Suellen D'arc Santos, et al.
Publicado: (2014)

Fexinidazole: A Potential New Drug Candidate for Chagas Disease
por: Bahia, Maria Terezinha, et al.
Publicado: (2012)

Galectin-3 and fibrosis intensity in Chronic Chagas Cardiomyopathy: a systematic review
por: Chaves, Ana Thereza, et al.
Publicado: (2022)

Trypanosoma cruzi trans-Sialidase as a Potential Vaccine Target Against Chagas Disease
por: da Costa, Kelli Monteiro, et al.
Publicado: (2021)

Application of WHO International Biological Reference Standards to evaluate commercial serological tests for chronic Chagas disease
por: Sáez-Alquezar, Amadeo, et al.
Publicado: (2020)

Differential Regional Immune Response in Chagas Disease
por: de Meis, Juliana, et al.
Publicado: (2009)

The association between variables of cardiopulmonary exercise test and quality of life in patients with chronic Chagas cardiomyopathy (Insights from the PEACH STUDY)
por: Vieira, Marcelo Carvalho, et al.
Publicado: (2022)

Long-Term Follow-Up of Patients with Chronic Chagas Disease and Implantable Cardioverter-Defibrillator
por: Pereira, Francisca Tatiana Moreira, et al.
Publicado: (2014)

New Biomarker in Chagas Disease: Extracellular Vesicles Isolated from Peripheral Blood in Chronic Chagas Disease Patients Modulate the Human Immune Response
por: Madeira, Rafael Pedro, et al.
Publicado: (2021)

Karyotype Evolution in Triatominae (Hemiptera, Reduviidae): The Role of Chromosomal Rearrangements in the Diversification of Chagas Disease Vectors
por: dos Reis, Yago Visinho, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8gu8adq5n7h4pdbcs82f7uau3u